Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

Search Results - irfan+asangani

1 Results Sort By:

Therapy overcoming resistance of refractory prostate cancer

Inhibition of cyclin-dependent-kinase 7 (CDK7) for treatment of refractory castration-resistant prostate cancer (CRPC) through reduction of androgen receptor transcriptional activity. Technology Overview: Prostate cancer is the most common non-cutaneous malignancy, and the second leading cause of cancer-related death in men of the western world....

Published: 7/15/2019

Inventor(s):

Keywords(s):

 

Category(s):